Back
Full-text
Journal article

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.

  • Shaw DE Respiratory Research Unit, University of Nottingham, Nottingham, UK Joint first authors dominic.shaw@nottingham.ac.uk.
  • Sousa AR Respiratory Therapeutic Unit, GSK, Stockley Park, UK Joint first authors.
  • Fowler SJ Respiratory and Allergy Research Group, University of Manchester, Manchester, UK.
  • Fleming LJ National Heart and Lung Institute, Imperial College, London, UK.
  • Roberts G NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, UK Faculty of Medicine, University of Southampton, Southampton, UK The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK.
  • Corfield J AstraZeneca R&D, Mölndal, Sweden Areteva R&D, Nottingham, UK.
  • Pandis I Data Science Institute, South Kensington Campus, Imperial College London, London, UK.
  • Bansal AT Acclarogen Ltd, St John's Innovation Centre, Cambridge, UK.
  • Bel EH Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Auffray C European Institute for Systems Biology and Medicine, CNRS-ENS-UCBL, Université de Lyon, Lyon, France.
  • Compton CH Respiratory Therapeutic Unit, GSK, Stockley Park, UK.
  • Bisgaard H Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Bucchioni E Chiesi Pharmacueticals SPA, Parma, Italy.
  • Caruso M Dept of Clinical and Experimental Medicine Hospital University, University of Catania, Catania, Italy.
  • Chanez P Département des Maladies Respiratoires, Laboratoire d'immunologie, Aix Marseille Université Marseille, Marseille, France.
  • Dahlén B Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Dahlen SE The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Dyson K CROMSOURCE, Stirling, UK.
  • Frey U University Children's Hospital Basel, Basel, Switzerland.
  • Geiser T University Hospital Bern, Bern, Switzerland.
  • Gerhardsson de Verdier M AstraZeneca R&D, Mölndal, Sweden.
  • Gibeon D National Heart and Lung Institute, Imperial College, London, UK.
  • Guo YK Data Science Institute, South Kensington Campus, Imperial College London, London, UK.
  • Hashimoto S Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Hedlin G Dept of Women's and Children's Health and Center for Allergy Research, Karolinska Institutet, Stockholm, Sweden.
  • Jeyasingham E UK Clinical Operations, GSK, Stockley Park, UK.
  • Hekking PP Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Higenbottam T Allergy Therapeutics, West Sussex, UK.
  • Horváth I Dept of Pulmonology, Semmelweis University, Budapest, Hungary.
  • Knox AJ Respiratory Research Unit, University of Nottingham, Nottingham, UK.
  • Krug N Fraunhofer Institute for Toxicology and Experimental Medicine Hannover, Hannover, Germany.
  • Erpenbeck VJ Translational Medicine - Respiratory Profiling, Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • Larsson LX AstraZeneca R&D, Mölndal, Sweden.
  • Lazarinis N Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Matthews JG Respiratory and Allergic Diseases, Product Development Immunology, Genentech, San Francisco, CA, USA.
  • Middelveld R CROMSOURCE, Stirling, UK.
  • Montuschi P Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
  • Musial J Dept of Medicine, Jagiellonian University Medical College, Krakow, Poland.
  • Myles D Respiratory Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.
  • Pahus L Assistance publique des Hôpitaux de Marseille, Hôpital NORD, Clinique des bronches, allergies et sommeil, Marseille, France.
  • Sandström T Dept of Medicine, Dept of Public Health and Clinical Medicine Respiratory Medicine Unit, Umeå University, Umeå, Sweden.
  • Seibold W Boehringer Ingelheim Pharma GmbH & Co., Ingelheim, Germany.
  • Singer F University Children's Hospital Zurich, Zurich, Switzerland.
  • Strandberg K Lung/Allergy Clinic, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Vestbo J Respiratory Research Group, Manchester Academic Health Science Centre, University Hospital South Manchester NHS Foundation Trust, Manchester, UK.
  • Vissing N The Danish Pediatric Asthma Center, University of Copenhagen, Copenhagen, Denmark.
  • von Garnier C University Hospital Bern, Bern, Switzerland Tiefenau Hospital, Bern, Switzerland.
  • Adcock IM National Heart and Lung Institute, Imperial College, London, UK Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UK.
  • Wagers S BioSci Consulting, Maasmechelen, Belgium.
  • Rowe A Janssen Research and Development Ltd, High Wycombe, UK.
  • Howarth P NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Wagener AH Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
  • Djukanovic R NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Sterk PJ Dept of Respiratory Medicine, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands Joint last authors.
  • Chung KF National Heart and Lung Institute, Imperial College, London, UK Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, UK Joint last authors.
Show more…
  • 2015-09-12
Published in:
  • The European respiratory journal. - 2015
Adrenal Cortex Hormones
Adult
Anti-Asthmatic Agents
Anxiety
Asthma
Case-Control Studies
Comorbidity
Cross-Sectional Studies
Depression
Europe
Female
Gastroesophageal Reflux
Humans
Male
Middle Aged
Nitric Oxide
Prospective Studies
Quality of Life
Severity of Illness Index
Smoking
Spirometry
Surveys and Questionnaires
Systems Biology
English U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical companies and six patient organisations with the objective of improving the understanding of asthma disease mechanisms using a systems biology approach.This cross-sectional assessment of adults with severe asthma, mild/moderate asthma and healthy controls from 11 European countries consisted of analyses of patient-reported outcomes, lung function, blood and airway inflammatory measurements.Patients with severe asthma (nonsmokers, n=311; smokers/ex-smokers, n=110) had more symptoms and exacerbations compared to patients with mild/moderate disease (n=88) (2.5 exacerbations versus 0.4 in the preceding 12 months; p<0.001), with worse quality of life, and higher levels of anxiety and depression. They also had a higher incidence of nasal polyps and gastro-oesophageal reflux with lower lung function. Sputum eosinophil count was higher in severe asthma compared to mild/moderate asthma (median count 2.99% versus 1.05%; p=0.004) despite treatment with higher doses of inhaled and/or oral corticosteroids.Consistent with other severe asthma cohorts, U-BIOPRED is characterised by poor symptom control, increased comorbidity and airway inflammation, despite high levels of treatment. It is well suited to identify asthma phenotypes using the array of "omic" datasets that are at the core of this systems medicine approach.
Language
  • English
Open access status
bronze
Identifiers
Persistent URL
https://sonar.ch/global/documents/278604
Statistics
Document views: 50 File downloads:
  • Full-text: 0